Moderna’s mRNA vaccine technology offers potential advantages in efficacy, speed of development, and production scalability and reliability.

mRNA-based vaccines offer several advantages, including:

• Ability to mimic many aspects of natural viral infections.

mRNA enters cells and is used to produce viral antigen proteins from within the cell that include natural, post-translational modifications. This can potentially enhance the immune response, including improved B and T cell responses.

• Multiplexing of mRNA for more compelling product profiles.

Multiple mRNAs encoding for multiple viral proteins can be included in a single vaccine, permitting production of complex multimeric antigens that are much more difficult to achieve with traditional technologies.

•  Rapid discovery and advancement of mRNA programs into the clinic.

Many viral antigens are known. Moderna claimed their ability to design their antigens in silico allows them to rapidly produce and test antigens in preclinical models, which can dramatically accelerate our vaccine selection.

• Capital efficiency and speed from shared manufacturing processes and infrastructure.

Moderna claimed their mRNA vaccines are produced in a manufacturing process that is sufficiently consistent across our pipeline to allow us to use a single facility to produce all of our mRNA vaccines.

Notes:

No mRNA vaccine has ever been approved for an infectious disease, and Moderna has never brought a product to market. But proponents of the vaccine say it could be easier to mass produce than traditional vaccines.

Source:

https://www.modernatx.com/